Maxime Dely: Anticoagulant Is an Invisible Yet Essential Ally of Therapeutic Apheresis
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Anticoagulant: the invisible yet essential ally of therapeutic apheresis
At first glance, one might think it’s normal saline.
Pearling drops, a steady flow, almost reassuring. And yet… what you’re seeing is far more than a simple solution.
It is an anticoagulant, a fundamental pillar of therapeutic apheresis procedures: ACD-A (Acid Citrate Dextrose – Solution A).
Its mission is clear and essential: to prevent blood from clotting in the extracorporeal circuit during apheresis.
Without it, safe blood processing would simply not be possible.
In practice, anticoagulation ratios can be adjusted depending on the procedure. But not all procedures are equal in terms of duration.
Plasma exchange or red cell exchange typically last 1 to 2 hours.
However, during hematopoietic stem cell collections or lymphocyte collections for CAR-T cell manufacturing, patients may remain connected to the machine for 3 to 6 hours, sometimes processing up to three mass of total blood volumes to achieve the required cell yield.
The specificity of ACD-A?
Citrate chelates calcium, which may lead to hypocalcemia: perioral tingling, metallic taste, chills, tremors… and potentially more severe symptoms if not anticipated.
This is why true expertise in apheresis is essential.
Optimizing a procedure means finding the right balance between collection efficiency, clinical safety, and patient comfort.
It requires close collaboration between nurses, physicians… and industry partners.
Because in apheresis, every single drop matters.”
Stay updated with Hemostasis Today.
-
Jun 27, 2026, 18:19Nabil Tabish: The Paradox of Zero – Investigating Extreme VWF Discordance
-
Jun 27, 2026, 18:19Francesco Favruzzo: Can Mechanical Thrombectomy Be Safely Used in Cervical Artery Dissection?
-
Jun 27, 2026, 18:18Vera Ghali: 2026 ASH–ISTH Recommendations on Pediatric VTE Prevention
-
Jun 27, 2026, 18:17Michiel Coppens: A Hemostasis Laboratory – One of the Cornerstones of Our Hemophilia Mission
-
Jun 27, 2026, 18:16Sthanu Subramanian: Dabigatran and Mechanical Heart Valves
-
Jun 27, 2026, 15:50Muhammet Özbilen: The Skin as an Emerging Regulator of Iron Homeostasis
-
Jun 27, 2026, 15:07Anteneh Berhane: Supporting Healthier Pregnancies Through Early Nutrition
-
Jun 27, 2026, 14:35Mobina Nakhaei: Why Alloantibodies Develop Despite ABO/Rh Matching in Thalassemia
-
Jun 27, 2026, 14:01Abdul Mannan: DOACs in Cancer-Associated VTE – When to Avoid Them, And When LMWH Wins